(S)-4-amino-N(4,4-dimethyl-cyclohexyl)glutamic acid | 163000-63-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-4-amino-N(4,4-dimethyl-cyclohexyl)glutamic acid
• 英文别名: (2S,4S)-2-amino-4-[(4,4-dimethylcyclohexyl)amino]pentanedioic acid
• CAS: 163000-63-3
• 化学式: C₁₃H₂₄N₂O₄
• 分子量: 272.345
• InChiKey: NTCVVGBUOCVHTI-UWVGGRQHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.1
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• USE OF NEBOGLAMINE (CR 2249) AS AN ANTIPSYCHOTIC AND NEUROPROTECTIVE
  申请人：ROTTAPHARM S.P.A.

  公开号：EP1755583A1

  公开（公告）日：2007-02-28
• USE OF NEBOGLAMINE FOR THE TREATMENT OF SCHIZOPHRENIA
  申请人：ROTTAPHARM S.P.A.

  公开号：EP1755583B1

  公开（公告）日：2010-04-14
• USE OF NEBOGLAMINE IN THE TREATMENT OF TOXICODEPENDENCY
  申请人：ROTTAPHARM S.P.A.

  公开号：EP1940376B1

  公开（公告）日：2009-03-18
• Use of Neboglamine (Cr 2249) as an Antipsychotic and Neuroprotective
  申请人：Makovec Francesco

  公开号：US20070249715A1

  公开（公告）日：2007-10-25

  Use of neboglamine, (S)-4-amino-N-(4,4-dimethylcyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), of the racemate thereof or of a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of schizophrenia.
• Use of Neboglamine in the Treatment of Toxicodependency
  申请人：Makovec Francesco

  公开号：US20100197962A1

  公开（公告）日：2010-08-05

  Use of neboglamine, (S)-4-amino-N(4,4-dimethyl-cyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the treatment of toxicodependency induced by drugs such as CNS sedatives such as opiates, barbiturates, benzodiazepines, alcohol, stimulants such as amphetamines and cocaine, and hallucinogens such as LSD, mescalin, cannabis (marijuana) or fencyclidine.